Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422451 | 0.77 | CNR1 (0.38) | POLBRAB9AKDM4EALDH1A1NPC1 | |
| SCHEMBL5898991 | 0.76 | GRM4 (0.60) | RAB9AKDM4ENPC1SMN1; SMN2KDR | |
| SCHEMBL30834279 | 0.76 | RAB9A (0.73) | POLBRAB9AKDM4EALDH1A1NPC1 | |
| SCHEMBL27720298 | 0.75 | HIF1A (0.59) | RAB9ANPC1SMN1; SMN2EGFR | |
| SCHEMBL129083 | 0.75 | — | — | |
| SCHEMBL1898971 | 0.75 | KMT2A (0.56) | RAB9AALDH1A1NPC1SMN1; SMN2KMT2A | |
| SCHEMBL483178 | 0.74 | PTPN1 (0.66) | POLBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL231897 | 0.74 | KDR (0.78) | POLBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL29184186 | 0.73 | KDR (0.76) | POLBRAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL752887 | 0.72 | CHRM2 (0.44) | RAB9AKDM4EALDH1A1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
| US-10100095-B2 | Resistant mutant 90 kDa heat shock protein | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20160311871-A1 | RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-3064582-A1 | RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-09-07 | — | — | EP | disclosed |
| EP-2662357-B1 | BICYCLIC COMPOUNDS OR SALTS THEREOF FOR USE IN THE TREATMENT OF CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-8912181-B2 | Bicyclic compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-12-16 | — | — | US | disclosed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2662357-A1 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-11-13 | — | — | EP | disclosed |
| US-20130296320-A1 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311871-A1 | RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN | HSP90AB1, HSP90AA1, HSP90AB2P | POLB 1575/4885RAB9A 3162/4885KDM4E 2950/4885 |
| US-10100095-B2 | Resistant mutant 90 kDa heat shock protein | HSP90AB1, HSP90AA1, HSP90AB2P | POLB 1575/4885RAB9A 3162/4885KDM4E 2950/4885 |
| US-20130296320-A1 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF | HSP90AB1, HSP90AA1, HSP90AB2P | POLB 4240/4885RAB9A 979/4885KDM4E 3917/4885 |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | POLB 1182/4885RAB9A 677/4885KDM4E 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.